Several reports have shown that the special tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR), is capable of reducing BMs in NSCLC, sometimes with a highly dramatic response [13–15]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.